Kymera Therapeutics KYMR Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $34.37M+1,097% | $2.87M+3.8% | $2.76M-75.9% | $11.48M-48.1% | $22.1M+199% | ||
| $98.16M+17.1% | $83.83M+13.1% | $74.09M-5.5% | $78.39M-2.3% | $80.26M+11.7% | ||
| $20.36M+20.2% | $16.94M-2.3% | $17.34M-1.8% | $17.65M+8.4% | $16.27M-0.4% | ||
| —— | $0-100% | $3.86M— | $0— | $0— | ||
| $118.52M+17.6% | $100.77M+5.8% | $95.29M-0.8% | $96.03M-0.5% | $96.53M+9.5% | ||
| $118.52M+17.6% | $100.77M+5.8% | $95.29M-0.8% | $96.03M-0.5% | $96.53M+9.5% | ||
| -$84.15M+14.0% | -$97.9M-5.8% | -$92.52M-9.4% | -$84.56M-13.6% | -$74.43M+7.8% | ||
| -244.9%+3,166pp | -3,411%-63.7pp | -3,347.4%-2,611pp | -736.8%-400pp | -336.8%+755pp | ||
| $14.92M+36.7% | $10.92M+5.5% | $10.35M+30.3% | $7.94M-10.2% | $8.85M-11.6% | ||
| -$69.23M+20.4% | -$86.98M-5.8% | -$82.18M-7.3% | -$76.61M-16.8% | -$65.58M+7.3% | ||
| -201.5%+2,829pp | -3,030.7%-57.7pp | -2,973%-2,305pp | -667.6%-371pp | -296.7%+660pp | ||
| -$0.71+27.6% | -$0.98-4.3% | -$0.94+1.1% | -$0.95-15.9% | -$0.82+7.9% | ||
| -$0.71+27.6% | -$0.98-4.3% | -$0.94+1.1% | -$0.95-15.9% | -$0.82+7.9% | ||
| 97.5M+15.4% | 84.5M-3.2% | 87.3M+8.5% | 80.4M+0.4% | 80.1M+6.8% | ||
| 97.5M+15.4% | 84.5M-3.2% | 87.3M+8.5% | 80.4M+0.4% | 80.1M+6.8% | ||
| -$75.23M+13.2% | -$86.68M-7.1% | -$80.95M-6.1% | -$76.28M-18.9% | -$64.15M+13.5% | ||
| $61K-32.2% | $90K-8.2% | $98K-9.3% | $108K+50.0% | $72K+22.0% | ||
| $14.98M+36.1% | $11.01M+5.4% | $10.44M+29.7% | $8.05M-9.7% | $8.92M-11.4% | ||
| $14.92M+36.7% | $10.92M+5.5% | $10.35M+30.3% | $7.94M-10.2% | $8.85M-11.6% | ||
| $34.37M+1,097% | $2.87M+3.8% | $2.76M-75.9% | $11.48M-48.1% | $22.1M+199% | ||
| -$84.15M+14.0% | -$97.9M-5.8% | -$92.52M-9.4% | -$84.56M-13.6% | -$74.43M+7.8% | ||
| -$82.13M+14.3% | -$95.86M-6.1% | -$90.37M-9.6% | -$82.47M-13.9% | -$72.38M+8.1% | ||
| -$82.13M+14.3% | -$95.86M-6.1% | -$90.37M-9.6% | -$82.47M-13.9% | -$72.38M+8.1% | ||
| -239%+3,101pp | -3,340.2%-70.6pp | -3,269.6%-2,551pp | -718.7%-391pp | -327.5%+738pp | ||
| -$84.15M+14.0% | -$97.9M-5.8% | -$92.52M-9.4% | -$84.56M-13.6% | -$74.43M+7.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Kymera Therapeutics's revenue?
- Kymera Therapeutics (KYMR) generated $51.5M in revenue over the trailing twelve months, down 12.6% year over year.
- Is Kymera Therapeutics profitable?
- Kymera Therapeutics is not currently profitable: it reported a net loss of $315.0M over the trailing twelve months, a -612.0% net margin.
- What is Kymera Therapeutics's earnings per share?
- Kymera Therapeutics's diluted EPS over the trailing twelve months is $-3.58.
- Where does Kymera Therapeutics's income statement data come from?
- Every line is extracted from Kymera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
